Investing.comDoubao · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 20:08:38·⟳ 抓取 20:09:20 +42s·⚡ 决策 10-22 20:11:53 +2m33s·5.4 天前
Celularity补交10-Q后获纳斯达克确认恢复定期报告合规，三项上市缺陷全部了结
本条Investing.com报道与72小时内已处理的GlobeNewswire官方通稿（2026-10-22 12:06 UTC，本臂已决策不做CELU.US）为同一具体事件：纳斯达克确认5250(c)(1)合规、三项缺陷全部关闭。本条无任何新增金额、指引、官方新动作或监管进展，仅为聚合站（且AI生成）对通稿的转述。事件本身是程序性合规修复（利空出尽式relief），10-Q已于10-20提交、另两项缺陷9月11日已关闭，无基本面增量；公司持续经营存重大不确定性、现金枯竭、收入下滑，约4090万美元市值、日均成交极低，盘前亦不可成交，双向无正期望。
📄 原文Investing.com↗ 原文
Celularity regains Nasdaq compliance after late filing
FLORHAM PARK, N.J. - Celularity Inc. (NASDAQ:CELU) received confirmation from Nasdaq that it has regained compliance wi…
不做 Celularity Inc.（CELU.US）
与72小时内已处理的GlobeNewswire官方通稿为同一合规恢复事件、无新增事实（NO_INCREMENTAL_FACT）；程序性合规恢复无基本面增量，10-Q已提交、另两项缺陷9月已关闭，且公司going concern、现金枯竭、收入下滑、流动性极差、美股盘前不可成交，双向无正期望，不做多亦无强空催化
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
同一合规恢复事件已在2分钟前经官方通稿研判并判不做，本条Investing.com聚合转述无新增事实；属无基本面增量的程序性relief，叠加going concern与极差流动性，不做多也无强空催化。
🔎 新鲜度:最早出现 2026-10-22 · 扩散 medium · price-in 风险 high
主要风险
- 若10-Q内容或盘前出现未被通稿覆盖的新增融资/药品利好，本条结论需重估，但当前无此事实
- 小盘生物股可能有合规解除的情绪脉冲，但流动性极差、止损不可靠，追高只承担回落风险
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-10-20 · 影响 weakens
已处理的10-Q显示持续经营重大不确定性、现金58.6万美元、营运资金赤字5329万美元、Q2收入同比降5.3%，基本面不支持做多；合规解除仅为relief
检索:CELU 10-Q going concern cash revenue 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:重复事件无新增边际，先例不改变不做结论
方向:无可对照外部先例，且本条为重复事件早停，不再补做先例研究
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 8,483 ms
{"result": "search_processed_events:agent query=`celularity celu nasdaq compliance regained 10-q late filing | celularity listing rule 5250(c)(1) compliance deficiency closed | celularity 纳斯达克 合规 财报 逾期`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、26094 条本臂决策(完整)，返回 2 条候选。\n• 10-22 12:06 UTC(北京 20:06) [bm25:
原文全文
展开原文 · 1,717 字
FLORHAM PARK, N.J. - Celularity Inc. (NASDAQ:CELU) received confirmation from Nasdaq that it has regained compliance with listing requirements following the filing of its second-quarter 2026 Form 10-Q, according to a press release statement.
The Listing Qualifications Staff of The Nasdaq Stock Market confirmed that Celularity met Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the U.S. Securities and Exchange Commission. The company filed its Quarterly Report on Form 10-Q for the period ended June 30, 2026 on Monday.
Nasdaq confirmed the reporting deficiency matter is closed. The company previously regained compliance with minimum bid price requirements under Nasdaq Listing Rule 5550(a)(2) and minimum market value of listed securities requirements under Nasdaq Listing Rule 5550(b)(2) on September 11, 2026.
"We have repeatedly fallen short of our obligation to provide timely financial reporting, and I take responsibility for that," said Robert J. Hariri, Chairman and Chief Executive Officer of Celularity. "Our shareholders deserve better."
Hariri stated the company has begun overhauling its finance organization to establish reporting discipline. Philip A. Barach, a recently appointed director and investor in Celularity, said the board is working to identify experienced finance professionals.
Celularity develops allogeneic and autologous cell therapies derived from the postpartum placenta. The company operates a cGMP research and manufacturing facility in Florham Park, New Jersey.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Celularity regains Nasdaq compliance after late filing
The Listing Qualifications Staff of The Nasdaq Stock Market confirmed that Celularity met Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the U.S. Securities and Exchange Commission. The company filed its Quarterly Report on Form 10-Q for the period ended June 30, 2026 on Monday.
Nasdaq confirmed the reporting deficiency matter is closed. The company previously regained compliance with minimum bid price requirements under Nasdaq Listing Rule 5550(a)(2) and minimum market value of listed securities requirements under Nasdaq Listing Rule 5550(b)(2) on September 11, 2026.
"We have repeatedly fallen short of our obligation to provide timely financial reporting, and I take responsibility for that," said Robert J. Hariri, Chairman and Chief Executive Officer of Celularity. "Our shareholders deserve better."
Hariri stated the company has begun overhauling its finance organization to establish reporting discipline. Philip A. Barach, a recently appointed director and investor in Celularity, said the board is working to identify experienced finance professionals.
Celularity develops allogeneic and autologous cell therapies derived from the postpartum placenta. The company operates a cGMP research and manufacturing facility in Florham Park, New Jersey.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Celularity regains Nasdaq compliance after late filing
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
8041d8389a· 2026-10-22 20:11 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前